Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal growth factor receptor and human epidermal growth factor...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical oncology Vol. 27; no. 33; p. 5538
Main Authors: Johnston, Stephen, Pippen, Jr, John, Pivot, Xavier, Lichinitser, Mikhail, Sadeghi, Saeed, Dieras, Veronique, Gomez, Henry Leonidas, Romieu, Gilles, Manikhas, Alexey, Kennedy, M John, Press, Michael F, Maltzman, Julie, Florance, Allison, O'Rourke, Lisa, Oliva, Cristina, Stein, Steven, Pegram, Mark
Format: Journal Article
Language:English
Published: United States 20.11.2009
Subjects:
ISSN:1527-7755, 1527-7755
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first